Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial

Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial

Background Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO‐001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of surgical oncology 2016-09, Vol.114 (3), p.336-341
Hauptverfasser: Postlewait, Lauren M., Ethun, Cecilia G., Kooby, David A., Sarmiento, Juan M., Chen, Zhengjia, Staley III, Charles A., Brutcher, Edith, Adsay, Volkan, El-Rayes, Bassel, Maithel, Shishir K.
Format: Artikel
Sprache:eng
Schlagworte:
Adenocarcinoma - metabolism
Adenocarcinoma - mortality
Adenocarcinoma - therapy
adjuvant chemotherapy
Aged
Antineoplastic Agents - toxicity
Biomarkers - metabolism
Chemotherapy, Adjuvant
Cisplatin - therapeutic use
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
DNA-Binding Proteins - metabolism
Drug Therapy, Combination
Endonucleases - metabolism
ERCC1
Feasibility Studies
Female
Humans
Male
Middle Aged
Pancreatectomy
pancreatic ductal adenocarcinoma
Pancreatic Neoplasms - metabolism
Pancreatic Neoplasms - mortality
Pancreatic Neoplasms - therapy
predictive markers
Predictive Value of Tests
Prospective Studies
recurrence
survival
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Standard adjuvant treatment for pancreatic adenocarcinoma (PDAC) is gemcitabine [Gem(CONKO‐001: Gem vs. placebo DFS:13.4 vs. 6.7 mo; P 
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.24317